Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 03 May 2017 Planned number of patients changed from 440 to 300.
- 03 May 2017 Planned End Date changed from 1 Sep 2018 to 30 Mar 2018.